Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are...
-
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are...
-
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such investors are...
-
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such...
-
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Such...
-
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) and...
-
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ:...
-
Fortis Life Sciences awards Deliver Biosciences the 2026 AbNano® VHH Discovery Grant for in vivo CAR-T, gene therapy & nanoparticle drug delivery research
-
TAMPA, Fla. and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing...
-
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated...